Cited by 269Antifungal resistance and susceptibilityFungal and yeast genetics researchYeasts and Rust Fungi Studies

Candida glabrata: A review of its features and resistance

Open access
Rodrigues, C. F., Silva, S., Henriques, M.·2014·European Journal of Clinical Microbiology & Infectious Diseases

Abstract

Candida species belong to the normal microbiota of the oral cavity and gastrointestinal and vaginal tracts, and are responsible for several clinical manifestations, from mucocutaneous overgrowth to bloodstream infections. Once believed to be non-pathogenic, Candida glabrata was rapidly blamable for many human diseases. Year after year, these pathological circumstances are more recurrent and problematic to treat, especially when patients reveal any level of immunosuppression. These difficulties arise from the capacity of C. glabrata to form biofilms and also from its high resistance to traditional antifungal therapies. Thus, this review intends to present an excerpt of the biology, epidemiology, and pathology of C. glabrata, and detail an approach to its resistance mechanisms based on studies carried out up to the present.

Integrity signals

Registry

Crossref · 10.1007/s10096-013-2009-3

Cites

155 of 155 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The first step of Candida glabrata biofilm development is adhesion and/or colonisation of yeast cells to an abiotic and/or biotic surface.

    “The first step of C. glabrata biofilm development is adhesion and/or colonisation of yeast cells to an abiotic or/and biotic surface [4,10].”

    From Candida glabrata Biofilms: How Far Have We Come? (2017) · cites this paper as [10]

  • Candida glabrata has high antifungal drug resistance.

    “In addition to the high antifungal drugs resistance and inability to form hyphae or secret hydrolases, C. glabrata retain many virulence factors”

    From Candida glabrata Biofilms: How Far Have We Come? (2017) · cites this paper as [10]

  • Candida glabrata retains many virulence factors that contribute to its extreme aggressiveness.

    “C. glabrata retain many virulence factors that contribute to its extreme aggressiveness and result in a low therapeutic response and serious recurrent candidiasis”

    From Candida glabrata Biofilms: How Far Have We Come? (2017) · cites this paper as [10]

  • Biofilms are very resistant to antifungal treatments.

    “For their extraordinary organization, especially regarding the complex structure of the matrix, biofilms are very resistant to antifungal treatments.”

    From Candida glabrata Biofilms: How Far Have We Come? (2017) · cites this paper as [10]

  • Biofilm formation ability is a virulence factor of Candida glabrata.

    “particularly biofilm formation ability”

    From Candida glabrata Biofilms: How Far Have We Come? (2017) · cites this paper as [10]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Rodrigues, C. F., Silva, S., & Henriques, M.
Affiliations
Institute for Biotechnology and Bioengineering (PT)
Corresponding author
Henriques, M.
Venue
European Journal of Clinical Microbiology & Infectious Diseases
Published
2013-11-19
Volume
33
Issue
5
Pages
673-688
ISSN
  • 0934-9723 (ISSN-L)
  • 1435-4373
OpenAlex
W2099290964
Cited by
268
References
155
Citations by year
2026: 11 · 2025: 10 · 2024: 23 · 2023: 17 · 2022: 25 · 2021: 28 · 2020: 27 · 2019: 24 · 2018: 34 · 2017: 24 · 2016: 19 · 2015: 16 · 2014: 10
FWCI
1.95
Type
journal article
Language
en
Open access
Locations
  • European Journal of Clinical Microbiology & Infectious Diseases (publishedVersion)
  • PubMed (publishedVersion)
  • Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Yeasts and Rust Fungi Studies
Keywords
Candida glabrata, antifungal resistance, biofilm, candidiasis, bloodstream infection, immunosuppression, fungal pathogenesis, yeast biology
MeSH terms
Antifungal Agents, Candidiasis, Humans, Drug Resistance, Fungal, Candida glabrata

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review